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Abstract
Background: Atrial fibrillation (AF) in the elderly is a complex condition. It has a direct impact on the underuse of
antithrombotic therapy reported in this population.
Discussion: All patients aged ≥75 years with AF have an individual yearly risk of stroke >4 %. However, the risk of
hemorrhage is also increased. Moreover, in this population it is common the presence of other comorbidities,
cognitive disorders, risk of falls and polymedication. This may lead to an underuse of anticoagulant therapy. Direct
oral anticoagulants (DOACs) are at least as effective as conventional therapy, but with lesser risk of intracranial
hemorrhage. The simplification of treatment with these drugs may be an advantage in patients with cognitive
impairment.
The great majority of elderly patients with AF should receive anticoagulant therapy, unless an unequivocal
contraindication. DOACs may be the drugs of choice in many elderly patients with AF.
Summary: In this manuscript, the available evidence about the management of anticoagulation in elderly patients
with AF is reviewed. In addition, specific practical recommendations about different controversial issues (i.e. patients
with anemia, thrombocytopenia, risk of gastrointestinal bleeding, renal dysfunction, cognitive impairment, risk of
falls, polymedication, frailty, etc.) are provided.
Keywords: Anticoagulation, Antithrombotic therapy, Apixaban, Atrial fibrillation, Dabigatran, Direct oral
anticoagulants, Edoxaban, Elderly, Rivaroxaban, Warfarin
Background
Atrial fibrillation (AF) is a common disease in the eld-
erly. Data from ATRIA (United States) and VAL-FAAP
(Europe) studies have shown that 9 % and 17.6 %,
respectively, of patients aged 80 years or older have this
condition [1, 2].
In AF patients, those individuals aged ≥ 75 years have
a worse prognosis compared with subjects between 65
and 74 years, with higher mortality and major adverse
cardiac events rates [3]. In fact, in a cohort of individuals
aged ≥75 years with AF in Sweden, mortality reached
18.2 % [4].
The risk of stroke is increased four- to five-fold in
patients with AF, particularly in elderly. Whereas AF ac-
counts for ≥15 % of all strokes in United States, these
numbers increase to 36 % for individuals aged >80 years
old. Remarkably, ischemic strokes associated to AF are
more likely to be chronically disabled, bedridden, and to
require constant nursing care, particularly in elderly [5].
Therefore, prevention of stroke is the most important
goal in these patients. In this context, anticoagulation
should be considered for most patients. However, age is
not only an independent predictor of stroke in AF
patients, but also of bleeding risk [6].
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AF is a complex condition in elderly subjects due to
their high number of comorbidities, including cardiovas-
cular and kidney diseases, cognitive disorders, falls and
polypharmacy [7]. As a result, the management of these
patients is challenging in most cases. Although the use
of anticoagulants has increased in the last years, they are
still underused in elderly population [8–11].
The aim of this update was to review the available
evidence about the management of anticoagulation in
elderly patients with AF and provide some practical rec-
ommendations about different controversial issues.
Evidence and recommendations
The answers to each question are presented here
Antithrombotic treatment
To determine the best therapeutic approach in individ-
uals with non-valvular AF, the risk of both, stroke and
bleeding should be determined in every patient, includ-
ing the elderly population. All patients aged >75 years
with AF have an individual yearly risk of stroke >4 % [6].
However, their risk of hemorrhage is also increased. In
fact, age has been included in CHA2DS2-VASc (1 point
for age 65-74 years; 2 points for age ≥75 years) and
HAS-BLED (1 point for age >65 years) scores [6, 12, 13].
Despite of this, unless the risk of bleeding is exceedingly
high, anticoagulation is required for most elderly
subjects [6].
Different studies have shown that anticoagulation is
much more effective than antiplatelet therapy to reduce
the risk of stroke in patients with AF at risk of arterial
thromboembolic complications, particularly in elderly
patients. In the ACTIVE-W trial, warfarin was superior
to clopidogrel plus aspirin for the prevention of vascular
events in patients with AF at high risk of stroke, espe-
cially in those subjects already taking oral anticoagula-
tion therapy [14]. In the BAFTA study, in 973 AF
patients aged 75 years or over, after a mean follow-up of
2.7 years, treatment with warfarin was associated with a
52 % reduction in the risk of fatal or disabling stroke,
intracranial haemorrhage, or clinically significant arterial
embolism, compared with aspirin 75 mg daily [15]. In
the AVERROES study, in which 5,599 patients with AF
(mean age 70 years) who were at increased risk for
stroke and for whom VKA therapy was unsuitable, apix-
aban reduced the risk of stroke or systemic embolism by
55 % compared to aspirin (81 to 324 mg per day), with-
out a significant increase in the risk of major bleeding
[16]. Importantly, it has been reported that acetylsalicylic
acid has no discernable protective effect against stroke
and may even increase the risk of ischaemic stroke in
elderly patients [17].
In summary, except when there is a high risk of bleed-
ing, anticoagulation is required in most elderly patients
with AF to prevent the risk of stroke. If anticoagulation
is contraindicated due to the very high risk of bleeding,
the use of antiplatelet drugs instead of anticoagulants is
not justified. Antiplatelet agents should only be consid-
ered in those elderly patients with AF who reject taking
anticoagulants and have concomitant vascular disease.
Finally, as these patients have an elevated risk of
bleeding, it is essential to identify those factors that
increase the risk of hemorrhage (i.e. high blood pres-
sure, concomitant use of non-steroidal anti-inflammatory
drugs, alcohol abuse, etc.) in order to modify them to re-
duce this risk.
Management of antithrombotic treatment in patients
with high risk of gastrointestinal bleeding
Due to age, comorbidities, and polymedication, patients
with AF have an increased risk of gastrointestinal bleed-
ing, a risk that is increased by antithrombotic treatment.
Treatment with VKA is associated with a three-fold
increase in risk of gastrointestinal hemorrhage. The
concomitant use of antiplatelets and VKA doubles the
risk compared with VKA alone [18–21].
Different meta-analyses have shown that, compared
with warfarin, new direct oral anticoagulants (DOACs)
provide significant reductions in stroke, intracranial
haemorrhage, and mortality, with similar major bleeding
risk and higher risk of gastrointestinal hemorrhages
[22–25], a finding not apparently observed in individ-
uals aged 75 years and older [26]. Of note, not all
DOACs have the same risk of gastrointestinal bleed-
ing, being apixaban the DOAC with the lesser risk
[25, 27–29]. In case of patients with history or at
high risk of gastrointestinal bleeding, vitamin K an-
tagonists should be considered.
To reduce the risk of gastrointestinal bleeding in pa-
tients taking anticoagulants, in those patients treated
with VKA, INR levels should be kept within the recom-
mended range over time. In case of treatment with
DOACs, dosage should be carefully taken according to
age (dabigatran and apixaban), creatinine clearance
(all DOACs) and previous history of gastrointestinal
bleeding. In addition, the use of non-steroidal anti-
inflammatory drugs, antiplatelet agents as well as alcohol
use should be avoided [20, 30–34].
Antithrombotic treatment in patients with anemia or
thrombocytopenia
It has been reported that decreased kidney function and
lower hemoglobin levels are associated with an increased
risk for new-onset AF, especially when both are present
[35]. On the other hand, thrombocytopenia is associated
with an increased risk of hemorrhage [36, 37]. In HAS-
BLED, bleeding refers to previous bleeding history and/or
predisposition to bleed (i.e. bleeding diathesis, anemia,
etc.) [6]. As a result, before beginning anticoagulation,
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both conditions should be investigated and corrected, if
possible.
Anticoagulation is generally contraindicated if platelet
count is <50x109/L. In ROCKET-AF, patients with
hemoglobin level <10 g/dL or platelet count < 90.000/μL
were excluded from the study [27]. In AVERROES and
RELY studies, patients with hemoglobin level <10 g/dL
or platelet count <100.000/mm3 were also excluded
[16, 28]. Therefore, in patients with platelet count
>100,000/dL, anticoagulation can be normally pre-
scribed. However, if platelet count is between 50,000
and 100,000/dL, the risk/benefit ratio should be care-
fully individualized.
Anemia predicts thromboembolic events, bleeding
complications and mortality in patients with atrial fibril-
lation [38]. Although anemia by itself should not be con-
sidered as an absolute contraindication for initiating
anticoagulation, it requires strict control and follow-up.
In fact, the history of anemia increases the risk of war-
farin interruption or discontinuation [39]. In patients
with mild anemia, it may be recommended to perform a
hemogram every 8-12 weeks immediately after anticoa-
gulation is started, and then at least every 6-12 months.
If hemoglobin levels remain stable, anticoagulation could
be continued.
Anticoagulation and renal function
Chronic kidney disease is common in patients with AF,
particularly in those individuals with permanent AF or a
CHA2DS2-VASc ≥2. A recent study showed that approxi-
mately one third of patients with CHA2DS2-VASc ≥2 had
moderate renal dysfunction [40]. Renal insufficiency in-
creases both, the risk of thromboembolic and bleeding
outcomes in patients with AF [41]. However, although
renal insufficiency is included in bleeding risk scores (i.e.
HAS-BLED), it has not been included in stroke risk scores
(i.e. CHA2DS2-VASc) [42, 43]. Remarkably, renal dysfunc-
tion does not contraindicate anticoagulation [44].
Dabigatran is contraindicated in patients with creatin-
ine clearance <30 ml/min and rivaroxaban, apixaban and
edoxaban are not recommended in subjects with creatin-
ine clearance <15 ml/min. DOACs can be safely used in
patients with moderate renal dysfunction, but dose
adjustment is required. In individuals with mild impair-
ment or normal renal function, no dose adjustment is
needed [45–47]. VKA can be used regardless of renal
impairment, and dose is adjusted only according to INR
values [48].
Renal function should be determined before starting
treatment with DOACs, and then at least every year, and
more frequently (at least once every 6 months) when
renal dysfunction exists, worsening renal function is sus-
pected, or in case of compromised patients, such as the
elderly or frailty [6, 49, 50].
Cognitive status and antithrombotic therapy
The risk for AF and cognitive disorders increases with
age. Different studies have reported a relationship be-
tween increased risk for cognitive impairment, dementia
and cardiovascular diseases, likely due to embolic
strokes or chronic cerebral hypoperfusion [51, 52]. AF
increases the risk of dementia. It has been estimated that
patients with AF have a 1.7 to 3.3 greater risk of cogni-
tive impairment, and a 2.3-fold increased risk of demen-
tia, compared to patients in sinus rhythm [53]. Different
mechanisms may explain this relationship. The con-
comitant presence of other cardiovascular risk factors
(i.e. hypertension, diabetes, obesity, hypercholesterol-
emia or smoking) increases the risk of new-onset AF
and stroke, and both, the risk of dementia. In addition,
AF is associated with silent cerebral infarctions and re-
duced brain volume [54–58].
A number of studies have shown that many patients
with cognitive impairment and AF are not anticoagu-
lated. However, dementia by itself should not be
considered as an absolute contraindication for anticoa-
gulation. Factors such as the severity of dementia, qual-
ity of life, life expectancy, and the presence of other
comorbidities should also be taken into account.
Importantly, these factors as well as the indication
of anticoagulation should be periodically reevaluated
[59–61].
On the other hand, worsening of cognitive function in
patients already taking VKA may be related with a poor
INR control. In these patients, DOACs could be of choice.
In addition, simplification of treatment with DOACs may
be an advantage in patients with cognitive impairment. Fi-
nally, the control of cardiovascular risk factors should also
be a target in this population [62–66].
Antithrombotic treatment in patients at risk of falls
Fall history, dependency in daily activities, age ≥75 years
and living alone are independent fall predictors in pa-
tients with AF [67]. Although frequent falls have been
associated with an increased risk of intracranial bleeding
and mortality in anticoagulated patients, the overall risk
remains low. In fact, this risk is generally lower than the
risk of stroke in elderly patients with AF. As a result,
risk stratification of stroke and bleeding is mandatory in
this population. The history of frequent falls requires the
identification of those factors that can be modified to re-
duce the risk of intracranial hemorrhage (i.e. drugs,
orthostatic hypotension, visual impairments, etc.). If
these factors are corrected, anticoagulation can be nor-
mally prescribed. If not, the decision should be individu-
alized [68–70].
We consider that in patients at risk of frequent
falls with a CHADS2 score ≥3, the beneficial effect
of anticoagulation is higher than the risk of
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intracranial hemorrhage. However, in patients with a
CHADS2 score ≥3 that had a post-traumatic intra-
cranial hemorrhage while taking anticoagulants,
anticoagulation should be permanently withdrawn.
By contrast, in those patients with a CHADS2 score
<2 and frequent falls, anticoagulation should be
avoided.
Compared with warfarin, DOACs have a lesser risk of
intracranial hemorrhage (33-69 % risk reduction depend-
ing on the drug), including traumatic intracranial bleed-
ing. As a result, it is reasonable to recommend, the use
of DOACs over VKA in patients with a high risk of falls
[71, 72].
Importance of blood pressure control
Since uncontrolled hypertension markedly increases the
risk of stroke, including hemorrhagic stroke, reducing
blood pressure to recommended targets is mandatory in
elderly patients with AF [73–76].
Since alert reaction at clinic may be common in elderly
patients taking anticoagulants, the use of ambulatory
blood pressure monitoring or 24-hour blood pressure
monitoring is recommended in this context. Blood pres-
sure should be controlled at office or with ambulatory
blood pressure monitoring, at least every month. On the
other hand, assuring an adequate treatment adherence is
mandatory [73–76].
In patients with blood pressure ≥180 /100 mmHg, the
beginning of anticoagulation should be postponed to
achieve blood pressure <160/90 mmHg. This reduction
should be attained as soon as possible. In patients already
taking anticoagulants, this reduction should be achieved
within a few days. The final target in elderly patients tak-
ing anticoagulants should be always <160/90 mmHg, and
preferably <140/90 mmHg when tolerated [77, 78]. Ortho-
static hypotension is common in elderly. Antihypertensive
treatment should be carefully prescribed in this popula-
tion in order to avoid orthostatic hypotension [78].
Table 1 Causes of permanent discontinuation and temporary interruption of anticoagulant therapy and conditions that do not
justify anticoagulation withdrawal
Temporary interruption ○ Acute major bleeding (life-threatening hemorrhage, bleeding leading to
hospital admission or need for blood transfusion).
○ Before elective surgery.
○ Before endoscopic procedures with high risk of hemorrhage
Permanent discontinuation ○ Hypersensitivity or intolerance to the drug.
○ Refusal of patient.
○ Medication non-adherence.
○ Poor short-term prognosis.
○ Advanced or terminal cancer.
○ Poor functional status with total dependency.
○ Advanced cognitive impairment.
○ Lack of social support that assure adequate drug compliance.
○ High risk of bleeding.
○ Retinopathy with high risk of bleeding.
○ Hepatic disease associated with coagulopathy and clinically relevant
bleeding risk.
○ Alcohol abuse.
Conditions that do not justify anticoagulation withdrawal
(but caution should be taken).
○ Comorbidities or frailty do not contraindicate anticoagulation. However,
life expectancy, functionality or cognitive impairment, among others,
should be considered.
○ Risk of falls.
○ Age (elderly).
○ Previous intracranial bleeding is not an absolute contraindication, except
when high risk of recurrence persists. If anticoagulation is considered, DOACs
should be preferred over VKA.
○ History of bleeding, particularly when the cause is eliminated.
○ Need for dual antiplatelet therapy (i.e. after stent implantation).
○ Concomitant use of nonsteroidal anti-inflammatory drugs.
New direct oral anticoagulants DOACs, vitamin K antagonists, VKA
Data taken from references #33,85-90
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Impact of polymedication and medication adherence
Polymedication is common in patients with AF, particu-
larly in elderly population. It has been estimated that AF
patients take nearly 7 drugs every day [2, 79].
Polymedication and complexity of treatment are asso-
ciated with poorer medication adherence. It has been
demonstrated that non-valvular AF patients treated with
once daily dosing regimens have approximately a 26 %
higher likelihood of adherence compared with subjects
on twice-daily regimens [80].
Interactions with other drugs are common in patients
taking VKA, but minimal with DOACs. In fact, up to 40 %
of patients taking VKA withdraw treatment after 5 years of
therapy. Compared with warfarin, medication adherence is
higher in those patients taking DOACs [81–84].
When should anticoagulation be interrupted?
In patients taking anticoagulants, stroke and bleeding
risk stratification should be periodically analyzed, re-
gardless of age. When bleeding risk overcomes the risk
of stroke, treatment should be discontinued. This deci-
sion should be taken together with patients and family
(Table 1). However, it should be noted that the
interruption of anticoagulation is associated with an in-
creased risk of death and thromboembolic complica-
tions. Finally, anticoagulation in patients with terminal
disease is not associated with an improved survival
[85–90]. This information should be carefully explained
to patients and family.
Utility of cranial computed tomography or magnetic
resonance in elderly patients who require anticoagulation
The prevalence of cerebral microhemorrhages, cerebral
white matter lesions (leukoaraiosis) and brain infarcts,
increases with age and are associated with a greater risk
of warfarin-related hemorrhage following ischemic
stroke [91–94]. Since DOACs are associated with a
lesser risk of intracranial bleeding compared with war-
farin [72, 95–98], it is very likely that patients with these
alterations would benefit more from DOACs. However,
no current data have confirmed this point. As a result, it
is not recommended to perform a cranial computed
tomography or magnetic resonance in all elderly patients
who require anticoagulation. Despite of that, if any of
these techniques are performed and these alterations are
detected, DOACs would be the treatment of choice.
Table 2 Dose adjustment of dabigatran, rivaroxaban and apixaban according to age, renal function and body weight
Drug Age Renal function Body weight
Dabigatran • <75 years: 150 mg b.i.d. • CrCl ≥50 mL/min: no dose adjustment
is necessary.
• No dose adjustment is necessary
according to body weight. However,
close clinical follow-up is required for
patients with a body weight <50 kg.• 75-80 years: 150 b.i.d. (110 mg b.i.d.
should be considered when the risk
of stroke is low and the bleeding
risk is high).
• CrCl 30-50 mL/min: the recommended
dose is 150 mg b.i.d. (110 mg b.i.d. for
patients with high risk of bleeding).
• ≥80 years: 110 mg b.i.d. • CrCl < 30 ml/min: contraindicated.
Rivaroxaban • No dose adjustment is required. • CrCl ≥50 mL/min: 20 mg o.d. • No dose adjustment is necessary
according to body weight.
• CrCl 15-49 mL/min: 15 mg o.d.
• CrCl <15 mL/min: not recommended.
Apixaban • Recommended dose: 5 mg b.i.d. • Recommended dose: 5 mg b.i.d. • Recommended dose: 5 mg b.i.d.
• 2.5 mg b.i.d. in case of at least 2
of the following characteristics:
age ≥80 years, body weight
≤60 kg, or serum creatinine
≥ 1.5 mg/dL.
• 2.5 mg b.i.d. in case of at least 2 of
the following characteristics: age
≥80 years, body weight ≤60 kg, or
serum creatinine≥ 1.5 mg/dL.
• 2.5 mg b.i.d. in case of at least 2 of
the following characteristics: age
≥80 years, body weight ≤60 kg, or
serum creatinine≥ 1.5 mg/dL.
• No dose adjustment is required
according to age, unless criteria
for dose reduction are met.
• No dose adjustment is necessary in
patients with mild or moderate renal
impairment, unless criteria for dose
reduction are met.
• No dose adjustment is required
according to body weight, unless
criteria for dose reduction are met
• CrCl 15-29 mL/min: 2.5 mg b.i.d.
• CrCl < 15 ml/min, or dialysis: not
recommended.
Edoxaban • No dose adjustment is required. • CrCl ≥50 mL/min: 60 mg o.d. • Body weight >60 kg: 60 mg o.d.
• CrCl 15-49 mL/min: 30 mg o.d. • Body weight ≤60 kg: 30 mg o.d.
• CrCl <15 mL/min: not recommended.
CrCl creatinine clearance, b.i.d. twice daily, o.d. once daily
Data taken from references #104-107
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Impact of frailty on treatment with DOACs
Up to 20 % of individuals aged ≥ 75 years in Spain are
considered as fragile patients [99]. Frailty is more com-
mon in elderly, women, widow, and patients with low
socioeconomic status, low educational level, comorbidi-
ties, polymedication, physical disability or cognitive im-
pairment. Age is the most common reason for not
prescribing anticoagulants in frail patients. Compared
with non-fragile patients, fragile individuals taking anti-
coagulants have an increased risk of bleeding, but also a
higher risk of stroke and death when not taking them.
As a result, frailty by itself should not contraindicate the
use of anticoagulants, but particular caution should be
taken in this population [99–103].
Impact of body weight on treatment with DOACs
With regard to body weight, dose adjustment of VKA
should be performed according to INR levels, but not to
body weight. By contrast, although no dose adjustment is
required in patients with body weight <50 Kg taking dabi-
gatran, a strict follow-up is recommended in these patients.
In individuals taking apixaban, the recommended dose is
2.5 mg twice daily in patients with at least two of the fol-
lowing characteristics: age ≥ 80 years, body weight ≤ 60 kg,
or serum creatinine ≥ 1.5 mg/dL. In patients with body
weight <60 Kg or estimated creatinine clearance of 30-
50 mL/min, the recommended dose of edoxaban is 30 mg.
Dose adjustment of rivaroxaban is not required according
to body weight (Table 2) [98, 104–107].
Do DOACs should be preferred over VKA in elderly
patients with AF?
Compared with warfarin, DOACs have a favorable risk-
benefit profile, with achievement of significant reduc-
tions in stroke, intracranial haemorrhage and mortality,
but similar major bleeding [25]. Although no specific
study has been performed in elderly population, different
substudies of pivotal phase-III clinical trials, with more
than 30,000 patients aged 75 years or older included,
have shown that compared with warfarin, the efficacy
and safety of DOACs in elderly patients were consistent
with that of the overall population [72, 95–98]. Since
DOACs have a wide therapeutic window, a predictable
anticoagulant effect and few interactions with other
drugs, these drugs may be preferable to VKA in many
elderly patients [108, 109].
However, patients included in clinical trials are quite
different from real-life patients (polymedication, comor-
bidities, cognitive impairment, frailty, etc.) [110].
Conclusions
Elderly patients with AF are at high risk of stroke. The
great majority of these patients should receive anti-
coagulant therapy, unless contraindication. However, AF
in the elderly is a complex condition due to the presence
of other comorbidities, cognitive disorders, risk of falls
and polymedication. This may explain, at least in part,
the underuse of anticoagulation reported in this popula-
tion. DOACs are at least as effective as conventional
therapy, but with lesser risk of intracranial hemorrhage.
In addition, the simplification of treatment with these
drugs may be an advantage in patients with cognitive
impairment. As a result, DOACs may be of choice in
many elderly patients with AF.
Due to the limited data, there are relevant gaps in the
management of elderly patients with AF. This update
tried to clarify them (Table 3).
Table 3 Main recommendations performed in elderly patients
with AF
• Except when the risk of bleeding is very high, anticoagulation is
required to prevent the risk of stroke in elderly patients with AF.
• Antiplatelet agents should only be considered in those patients who
reject taking anticoagulants and have concomitant vascular disease.
• It is essential to identify those factors that increase the risk of hemorrhage
(i.e. high blood pressure, concomitant use of non-steroidal
anti-inflammatory drugs, alcohol abuse, etc.) in order to modify
them to reduce this risk.
• To reduce the risk of gastrointestinal bleeding in patients taking
anticoagulants, VKA should be carefully controlled over time. In case
of treatment with DOACs, dosage should be carefully prescribed
according to age (dabigatran and apixaban) weight (dabigatran,
rivaroxaban and apixaban) and creatinine clearance (dabigatran,
rivaroxaban and apixaban). The use of non-steroidal anti-inflammatory
drugs or antiplatelet agents as well as alcohol abuse should be
avoided.
• In patients with platelet count >100,000/dL, anticoagulation can
be normally prescribed. If platelet count is between 50,000 and
100,000/dL, risk/benefit ratio should be carefully individualized.
• Anemia by itself should not be considered as an absolute
contraindication for initiating anticoagulation, but a strict control
and follow-up should be performed.
• DOACs can be safely used in patients with moderate renal dysfunction,
but dose adjustment is required. VKA can be used regardless renal
function.
• Dementia by itself should not be considered as an absolute
contraindication for anticoagulation. Factors such as the severity
of dementia, quality of life, life expectancy, and the presence of
other comorbidities should also be considered. These factors
should be periodically reevaluated.
• In patients at risk of frequent falls with a CHADS2 score ≥3, the beneficial
effect of anticoagulation is higher than the risk of intracranial hemorrhage.
By contrast, in those patients with a CHADS2 score <2 and frequent falls,
anticoagulation should be avoided. In this context, it is reasonable to
recommend the use of DOACs over VKA.
• Reducing blood pressure to recommended targets (<160/90 mmHg,
preferably <140/90 mmHg when tolerated) is mandatory in elderly
patients with AF.
• It is not recommended to perform a cranial computed tomography
or magnetic resonance in all elderly patients who require
anticoagulation.
• Frailty by itself should not contraindicate the use of anticoagulants,
but particular caution should be taken in this population
VKA vitamin K antagonists, DOACs new direct oral anticoagulants
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